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Abstract
Background: Stem cell characteristics are an important feature of human cancer cells and play a major role in the therapy
resistance of tumours. Strategies to target cancer stem cells are thus of major importance for cancer therapy. Differentiation
therapy by nucleoside drugs represents an attractive approach for the elimination of cancer stem cells. However, even if it is
generally assumed that the activity of these drugs is mediated by their ability to modulate epigenetic pathways, their
precise mode of action remains to be established. We therefore analysed the potential of three nucleoside analogues to
induce differentiation of the embryonic cancer stem cell line NTERA 2 D1 and compared their effect to the natural ligand
retinoic acid.
Methodology/Principal Findings: All nucleoside analogues analyzed, but not retinoic acid, triggered proteolytic
degradation of the Polycomb group protein EZH2. Two of them, 3-Deazaneplanocin A (DZNep) and 29-deoxy-5-azacytidine
(decitabine), also induced a decrease in global DNA methylation. Nevertheless, only decitabine and 1b-arabinofurano-
sylcytosine (cytarabine) effectively triggered neuronal differentiation of NT2 cells. We show that drug-induced
differentiation, in contrast to retinoic acid induction, is caused by caspase activation, which mediates depletion of the
stem cell factors NANOG and OCT4. Consistent with this observation, protein degradation and differentiation could be
counteracted by co-treatment with caspase inhibitors or by depletion of CASPASE-3 and CASPASE-7 through dsRNA
interference. In agreement with this, OCT4 was found to be a direct in-vitro-target of CASPASE-7.
Conclusions/Significance: We show that drug-induced differentiation is not a consequence of pharmacologic epigenetic
modulation, but is induced by the degradation of stem-cell-specific proteins by caspases. Our results thus uncover a novel
pathway that induces differentiation of embryonic cancer stem cells and is triggered by the established anticancer drugs
cytarabine and decitabine. These findings suggest new approaches for directly targeting the stem cell fraction of human
tumours.
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Introduction
Cancer is widely considered a developmental disease, caused by
the destabilisation of the balance of cellular proliferation and
differentiation [1,2]. Tumours thus originate from cells with stem
cell characteristics that have acquired aberrant gene expression
patterns, mostly due to mutations and epimutations. These
aberrant gene expression patterns lead to a block in differentiation
and trigger uncontrolled proliferation. Loss of differentiation is
thus an important characteristic of tumour cells and represents a
defining feature of human cancers. As a consequence, differenti-
ation therapy has been developed into an important approach for
the treatment of cancers, particularly leukaemias [3,4].
Stem cell features are controlled by a small group of
transcription factors, like NANOG and OCT4, that maintain
the expression of stem cell genes and repress the induction of
differentiation-specific genes by recruiting repressive complexes of
the Polycomb Group (PcG) [5,6]. Differentiation-associated genes
in mouse ES cells are repressed by PcG proteins and are often also
marked by DNA methylation [7]. These repressive marks are
successively lost during differentiation. A prominent example is the
loss of PcG repression at the HOXA gene cluster during neuronal
differentiation [8,9]. It has also been shown that promoters of
lineage-specific genes become methylated during differentiation,
suggesting context-dependent interactions between DNA methyl-
ation and Polycomb repression [10]. A key component of PcG
repression is the histone methyltransferase EZH2 (enhancer of
zeste homolog 2), the enzymatic core component of the Polycomb
repressive complex 2 (PRC2). This protein creates specific
trimethylation patterns of lysine 27 of histone H3 (H3K27me3),
which leads to concomitant transcriptional silencing [11,12].
The characterization of drugs that modulate epigenetic
processes and induce differentiation in human cancer cells
represents an important aspect in the development of epigenetic
cancer therapies. Retinoic acid (RA), which induces differentiation
in many stem cell populations, was among the first substances used
for differentiation therapy [3]. The seminal finding that the
differentiation-inducing cytosine analogue 29-deoxy-5-azacytidine
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methyltransferases provided an important link between cellular
differentiation and epigenetic regulation [13]. Another example is
3-Deazaneplanocin A (DZNep), which has been shown to cause
proteolytic degradation of PRC2 components, to influence histone
modification patterns and to induce moderate differentiation
effects in acute myeloid leukaemia cells [14–17]. DZNep was
originally synthesised as an inhibitor of S-adenosylhomocysteine
hydrolase (SAHH), a key enzyme in S-adenosylmethionine (SAM)
dependent methylation processes [18]. Treatment of MCF-7
breast cancer cells with DZNep led to the derepression of a defined
set of Polycomb targets, which again suggested that the compound
might also induce cellular differentiation [14]. While these findings
proposed a close connection between epigenetic modulation and
drug-induced differentiation, cytarabine (1 b-arabinofuranosylcy-
tosine, araC), a cytosine analogue closely related to decitabine,
effectively induces differentiation, without inhibiting DNA meth-
ylation [19]. Both decitabine and cytarabine have been shown to
be effective in the treatment of myeloid leukaemias, a group of
diseases that is characterised by a differentiation block of precursor
cells [20]. However, it is still not clear how these substances induce
cellular differentiation and whether the inhibition of epigenetic
modifiers plays a significant role in these mechanisms.
Over the past few years, the human embryonic teratocarcinoma
cell line NTERA2 D1 (NT2) has been established as an intriguing
human cancer stem cell model and represents a valuable tool for
the analysis of the mechanisms regulating cellular differentiation.
We have used NT2 cells, which can be induced to differentiate
with natural ligands, like retinoic acid [21], to characterise the
differentiation-inducing mechanisms triggered by RA, araC, DAC
and DZNep. The three nucleoside analogues caused degradation
of EZH2, but drug-induced differentiation could be observed only
for araC and DAC. The latter drugs became integrated into DNA
and induced DNA damage, which triggered the caspase-
dependent degradation of NANOG and OCT4. Our results
suggest that drug-induced differentiation is not a consequence of
pharmacologic inhibition of DNA methylation and/or histone
methylation but caused by the direct degradation of stem cell
factors. Our study uncovers a novel mechanism mediating cellular
differentiation by nucleoside drugs and suggests that cytarabine
and decitabine might be useful for targeting cancer stem cells.
Results
DAC and araC induce differentiation of NT2 EC cells
Embryonal carcinoma (EC) cells derived from teratocarcinomas
show many features of pluripotent cells and are often considered to
be the malignant counterpart of human embryonic stem cells [22].
The EC cell line NTERA D1 (NT2) is a subclone of the line
TERA2, originally derived from a lung metastasis associated with
a testicular germ cell tumour that was established from a nude
mouse xenocraft [23]. NT2 cells have not only been shown to
differentiate along the neuronal linage, but also have mesodermal
and ectodermal lineage potential. NT2 cells thus represent a
valuable stem cell and cancer stem cell model [22,24]. Morpho-
logical neuronal differentiation of NT2 cells with RA usually
requires several weeks of treatment [21]. Nevertheless, gene
expression patterns change rapidly, and strong derepression of the
anterior part of the PcG-repressed HOXA cluster becomes
detectable after a few hours and is accompanied by significant
epigenetic changes [8,9].
We assumed that activation of differentiation in NT2 cells would
require substantial epigenetic modulation, especially changes in PcG
presence, histone modification patterns and also DNA methylation.
We thus chose DZNep, a drug that has been shown to cause
degradation of the PcG protein EZH2 [14], and the established
DNA methylation inhibitor DAC as potential drugs to induce
differentiation. In addition, we used araC, an inhibitor of mitosis
and potent inducer of apoptosis [25], as a structurally related drug
with no direct epigenetic activity, and retinoic acid as a natural
differentiation-inducing agent. All three nucleoside drugs showed
similar, concentration-dependent cytotoxicity on NT2 cells and on
other human cancer cell lines (Figure S1). For further treatments of
NT2 cells we thus used drug concentrations equitoxic to the DZNep
concentration established previously [5 mM, ref. 14], i.e. 20 mMf o r
araC and 1 mM for DAC. Interestingly, we observed a neuron-like
morphology in NT2 cells following incubation with araC and DAC
already after 3 days, whereas treatment with DZNep and RA only
led to weak or no morphological differentiation effects (Figure 1A).
RT-PCR analysis of two neuronal markers known to be
prominently induced in differentiating NT2 cells [26–28], NEFL
(neurofilament light polypeptide) and SNAP25 (synaptosomal-
associated protein 25), demonstrated robust induction of both genes
following treatment with araC or DAC (Figure 1B). DZNep and RA
caused only minor activation of these genes, which is consistent with
the absence of neuronal morphology after 3 days of treatment with
both substances. These results establish araC and DAC, but not
DZNep, as strong inducers of neuronal differentiation in NT2 cells.
Analysis of drug-dependent changes in PcG repression
In order to identify the mechanisms that lead to drug-induced
differentiation, we first analysed the effects on PcG repression.
PRC2 degradation has been demonstrated for DZNep-treated
MCF7 breast cancer cells [14] and the release from PcG
repression is a molecular hallmark of differentiation [8,9]. All
three nucleoside drugs caused degradation of EZH2 after three
days of treatment at equitoxic concentrations whereas RA had
only a weak effect (Figure 2A). EZH2 degradation by these
compounds could also be observed in other human cancer cell
lines, although to varying degrees (Figure S2A). Drug treatment
did not significantly affect the level of EZH2 mRNA expression
(Figure 2B), which confirmed that drug-dependent EZH2
degradation is regulated at the protein level [14].
It has been suggested that DZNep-mediated EZH2 degradation
in MCF-7 cells might be related to the drug’s ability to inhibit S-
adenosylhomocyteine hydrolase (SAHH), a key enzyme in S-
adenosylmethionine dependent methylation processes [14]. In
order to determine the requirement of SAHH activity for EZH2
stability, we used siRNAs to efficiently deplete SAHH in NT2
cells. Subsequent Western analysis did not indicate any changes in
the EZH2 protein level and in H3K27 trimethylation (Figure 2C).
Similar results were also obtained in MCF-7 cells (Figure S2B).
These findings indicate that the pharmacologic activity of DZNep
is not limited to the inhibition of SAHH and that the molecular
mechanisms triggering DZNep-induced EZH2 degradation re-
main to be established.
The 59 genes of the HOXA cluster are among the first genes to
be activated by RA and show rapid loss of PcG complexes and
H3K27me3 upon in vitro differentiation [8,9]. We therefore
determined the expression levels of HOXA genes upon drug
treatment. As expected, the natural ligand RA triggered strong
expression in the 59-region of the cluster (Figure 3A). DAC and
araC also caused significant gene activation in a concentration-
dependent manner, whereas DZNep-induced changes were
relatively minor (Figure 3A and Figure S3A). These findings,
together with the effects on EZH2 stability, suggested that RA,
araC and DAC induce cellular differentiation independent of
EZH2 degradation. This was confirmed by siRNA-mediated
Drug-Induced Differentiation
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activation of the HOXA cluster (Figure 3A and S3B), indicating
that EZH2 degradation is not sufficient for cellular differentiation.
Reactivation of HOXA genes by RA is accompanied by
epigenetic changes in their histone modification patterns [8,9].
Cytarabine and DAC have not been reported to affect global
histone modifications. In contrast, DZNep has been shown to
cause genome-wide loss of H3K27me3 [14] and additional
repressive and active histone modifications [16]. We therefore
analysed the effect of drug treatment on the histone methylation
pattern of the HOXA1 promoter by chromatin immunoprecipita-
tion (ChIP). In control cells this region is marked by H3K27me3
and lacks the activating mark H3K4me3 (trimethylation of lysine 4
of histone H3), consistent with its silent state (Figure 3B). When
HOXA1 was induced by RA, the promoter was marked mainly by
H3K4me3. DZNep did not cause any significant changes, whereas
the HOXA1-activating drugs araC and DAC caused a substantial
increase in H3K4me3, in parallel with a reduction in H3K27me3
levels (Figure 3B). This indicates that drug-induced activation of
HOXA1 is accompanied by histone modification changes,
reflecting the loss of PcG repression at this target gene.
Analysis of drug-dependent DNA methylation changes
To further elucidate the pathways mediating drug-induced
differentiation we also investigated DNA methylation. Previous
studies have linked altered HOX gene expression patterns to
changes in the DNA methylation status [29–31]. In addition, it has
been suggested that DZNep might cause concomitant DNA
methylation changes [14]. Lastly, DAC is an established inhibitor
of DNA methylation and inhibition of DNA methylation has also
been associated with cellular differentiation [13]. We therefore
compared DZNep, araC, DAC and RA in their ability to alter
HOXA methylation in NT2 cells. Methylation analysis by COBRA
indicated dense DNA methylation of several HOXA CpG islands,
some of which were demethylated upon incubation with DZNep
or DAC, but not with araC or RA (Figure 4A). Similar results were
also obtained using capillary electrophoresis to measure global
cytosine methylation. Untreated NT2 cells showed a methylation
level of 4.3%, which was not significantly altered after treatment
with araC or RA (Figure 4B). However, treatment with DAC or
DZNep significantly reduced global DNA methylation levels to
2.4% and 3.2%, respectively (Figure 4B). These results provide
important confirmation for the DNA methylation inhibiting
activity of DZNep [14,16]. However, DZNep did not cause
degradation of DNA methyltransferase 1 (DNMT1) (Figure 4C),
which represents the main pathway for DAC-induced DNA
demethylation [32]. Interestingly, depletion of SAHH by RNA
interference (RNAi) also led to significant demethylation of HOXA
CpG islands (Figure 4D and Figure S3C), which suggests that the
demethylating activity of DZNep is a consequence of the
Figure 1. Nucleoside drugs araC and DAC induce neuronal differentiation of NT2 EC cells. (A) Microscopic images (106magnification) of
NT2 control cells (cont.) and NT2 cells treated with DZNep, araC, DAC or RA for 3 days. Neuron-like morphology appears most pronounced for araC and
DAC. (B) qRT-PCR expression analysis of neuronal differentiation markers NEFL and SNAP25 in drug-treated, RA- treated and control cells after 3 and 6
days of treatment. NEFL and SNAP25 are prominently induced by araC and DAC. All qRT-PCR measurements were repeated at least three times and
internally normalised to the corresponding lamin-b and b-actin expression levels. Deoxycytidine (dC) was included as a mock treatment control. Y-axis
shows fold expression changes compared to the untreated control (cont.). P-values (Student’s t-test) for the expression differences between control and
treated cells for highly significant cases (p#0.01) are shown. Asterisks indicate expression values that are significantly different from controls.
doi:10.1371/journal.pone.0010726.g001
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confirm the demethylating activity of DZNep and suggest that
DZNep-induced DNA demethylation is not related to DNMT1
degradation. Nevertheless, the lack of detectable araC-induced
methylation changes suggests that inhibition of DNA methylation
is not required for HOXA derepression and cellular differentiation.
Drug-induced differentiation of NT2 cells requires
degradation of stem cell factors
In our previous experiments we found differentiation by RA,
araC and DAC to be accompanied by a loss of PcG-repression at
the HOXA-cluster. However, RA did not trigger EZH2-depletion
and EZH2-degradation by DZNep did not lead to HOXA-
activation. This suggests that the drug-induced loss of PcG
repression is caused by an upstream event. A recent study
described the CASPASE-3-dependent degradation of the stem
cell-specific transcription factor NANOG as important for RA-
induced differentiation of human ES cells [33]. NANOG and the
core transcription factor OCT4 maintain the expression of stem
cell genes, and repress the induction of differentiation-specific
factors [5]. A reduction of NANOG and OCT4 protein levels is
thus a prerequisite for the induction of differentiation.
Both araC and DAC, but not DZNep [14], are incorporated
into DNA and have been shown to induce DNA damage,
apoptosis and proteolytic cascades [25]. Consistently, we observed
a robust accumulation of the DNA-damage marker cH2AX in
cells treated with araC and DAC (Figure 5A). As DNA-damage is
generally a trigger for caspase activation [34,35], we next
measured the enzymatic CASPASE-3/7 activity of drug-treated
cells. Indeed, treatment with araC and DAC led to a substantial
increase in caspase activity, while RA treatment had only a
moderate effect and DZNep did not lead to clear caspase
activation (Figure 5B). Of note, CASPASE-3/7 activation was
paralleled by an effective depletion of NANOG and OCT4
(Figure 5C and S4A). DZNep had no effect on cH2AX, NANOG
and OCT4, whereas RA-treatment did not lead to an increase of
cH2AX, but also reduced both stem cell factors (Figure 5A, 5C
and S4A). The lack of OCT4 reduction in DZNep-treated NT2
cells indicates that the mild morphological changes observed
(Figure 1A) are not due to differentiation processes. Downregu-
lation of NANOG and to lesser extent OCT4 by araC and DAC was
observed also at the mRNA level, while RA led to a very
pronounced transcriptional repression of both genes (Figure 5D).
To further distinguish between protein degradation and
regulation on the RNA level, we established a transfected NT2
cell line expressing EGFP under the control of the OCT4
regulatory region [36]. Untreated cells strongly expressed EGFP,
whereas treatment with retinoic acid for three days led to a
significant reduction of the EGFP-signal (Figure 5E), indicating
that OCT4 expression is silenced on the mRNA level. Treatment
with araC for the same period of time resulted in cellular
differentiation, but the cells retained significant EGFP expression
(Figure 5E), which is consistent with OCT4 downregulation at the
protein level.
In order to test if direct depletion of OCT4 and NANOG
induces differentiation of NT2 cells, we reduced the protein levels
of OCT4, NANOG, EZH2, DNMT1 and SAHH by dsRNA
interference and monitored neuronal morphology and expression
Figure 2. Nucleoside drugs affect EZH2 stability in NT2 cells. (A)
Western blot showing EZH2 in control (cont.) cells and cells treated with
dC, DZNep (DZN), araC, DAC and RA for 3 days. Reduced EZH2-levels
were observed for araC, DAC and DZNep. b-actin was used as loading
control, deoxycytidine (dC) as a mock treatment control. Below the
blots intensities of the EZH2-bands, normalised to the corresponding b-
actin bands, are indicated as percentage of the control (cont.). (B) EZH2
mRNA expression levels in NT2 cells upon 3 days of drug treatment do
not change significantly, as determined by quantitative RT-PCR. qRT-
PCR measurements with at least three biological replicates were
internally normalised to the corresponding lamin-b and b-actin
expression levels. Deoxycytidine (dC) was included as a mock treatment
control. (C) DZNep-mediated EZH2 depletion is not caused by SAHH
inhibition. Western blot showing the effect of SAHH depletion (kd
SAHH) on EZH2 and H3K27me3 levels in NT2 cells. Cells were treated for
72 hours with siRNAs. Knockdown of EZH2 (kd EZH2) was used as
positive control, b-actin and histone H3 (H3) were used as loading
controls. A mix of scrambled siRNAs was used as negative control (kd
cont.). Reduction of SAHH-levels has no effect on EZH2 stability or
H3K27me3 levels.
doi:10.1371/journal.pone.0010726.g002
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induce minor changes in SNAP25 expression, but only the
knockdown of OCT4 clearly induced neuronal differentiation,
and, in parallel, significantly increased expression of SNAP25
(Figure S5A and S5B). Combined knockdown of OCT4 and
NANOG or OCT4, NANOG and EZH2, did not enhance the
effect. NANOG expression is already strongly reduced in cells
depleted for OCT4 (Figure S5B), as OCT4 is a major activator of
the NANOG gene [5]. This also explains the lower levels of NANOG
transcription upon drug treatment (Figure 5D). Nevertheless,
depletion of stem cell factors, in particular OCT4, by RNAi shows
similar effects on NT2 cells as treatment with araC and DAC and
is sufficient to induce differentiation.
To confirm the involvement of proteolytic pathways in drug-
induced NANOG and OCT4 degradation, we analysed the
expression levels of several key regulatory factors of these pathways
in a time course experiment by RT-PCR. As expected, we
observed a significant induction of the CASPASE-7 gene by araC
and DAC, but also RA (Figure 6). Cytarabine and DAC also
triggered moderate upregulation of CASPASE-3 and the c-Jun N-
terminal kinase II (JNKII). This was paralleled by the expression of
the differentiation marker SNAP25 (Figure 6). We observed no
significant changes in gene expression for the apoptotic factor p53,
for c-Jun N-terminal kinase I (JNKI), CASPASE-9 and EZH2 (Figure 6).
Thus, CASPASE-7, and, to a lesser extent, CASPASE-3, seem to
be critical factors in araC- and DAC-induced degradation
processes.
Drug-induced differentiation is caused by CASPASE-7-
dependent degradation of OCT4
In order to further prove the role of caspases in drug-induced
differentiation, we combined nucleoside drug treatment with
caspase inhibitors (Inhibitor I and II) and a JNKII inhibitor (JNK
Inhibitor I). These substances caused a significant reduction of the
ability of araC or DAC to activate HOXA1 and SNAP25, whereas
RA-mediated induction of these genes and CASPASE-7 expression
was not significantly affected (Figure 7A). In addition, all three
inhibitors partially rescued OCT4- and EZH2-degradation
Figure 3. Nucleoside drugs affect Polycomb repression in NT2 cells. (A) qRT-PCR expression analysis of HOXA genes (1 to 13 - orthologs 8
and 12 are absent in the HOXA-cluster) after drug treatment for 3 days or knockdown of EZH2 (kd EZH2) for the same time period. Collinear activation
of the cluster, similar to RA-treatment (positive control), could only be observed for araC- and DAC-treated NT2 cells. All treatments and
measurements were repeated at least five times and internally normalised to the corresponding lamin-b and b-actin expression levels. Y-axis values
indicate fold induction compared to the non-treated control. Knockdown of EZH2 was repeated three times in independent experiments (see Figure
S3B). Deoxycytidine (dC) was included as a mock treatment control. (B) Chromatin immunoprecipitation (IP) analysis of the HOXA1 promoter region in
RA-, drug-treated and control NT2 cells. IP was repeated at least three times with chromatin from biological replicates using antisera specific for
H3K27me3 and H3K4me3. Immunoprecipitated DNA was analyzed by real time PCR and a primer specific for the HOXA1 promoter region.
Enrichments are shown as percentage of the total input.
doi:10.1371/journal.pone.0010726.g003
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for the reduction of OCT4 upon RA-treatment (Figure S4C),
which is consistent with the notion that OCT4 is downregulated
on the RNA level in RA-treated NT2 cells. DZNep has been
shown to trigger proteasomal degradation of PRC2 components
[14]. We thus also employed the proteasome inhibitor Lactacystin
[37]. We observed no an effect on araC- or DAC-induced
expression of HOXA1 or SNAP25 (Figure S6A) and Lactacystin did
not rescue araC-induced OCT4 or EZH2 degradation (Figure
S6B and S6C). In contrast, DZNep-induced EZH2 degradation
was affected by Lactacystin (Figure S6C), which is in line with the
established role of DZNep in inducing proteasome degradation
[14].
The rescue effects exerted by caspase and JNK inhibitors on
araC-induced differentiation could also be observed morpholog-
ically (Figure 7B). Combinatorial treatments with araC and
caspase inhibitors led to clearly less differentiated cells compared
to araC-treatment alone. Similar effects were observed when
CASPASE-3 and CASPASE-7 were depleted by corresponding
siRNAs in araC-treated cells (Figure S7A). NT2 cells induced to
differentiate with araC showed significantly less differentiated cells
when CASPASE-7 or both caspases were knocked down after
6 hours of araC-treatment and subsequent incubation for
48 hours (Figure S7A). In addition, combined knockdown of
CASPASE-3 and -7 in araC-induced NT2 cells led to significantly
lower activation of HOXA1 and SNAP25 (Figure S7B) and also
partially restored OCT4 protein levels in araC-treated NT2 cells
(Figure S7C).
In a final set of experiments we also tested if active recombinant
human CASPASE-7 or CASPASE-3 is able to degrade OCT4 or
NANOG in nuclear extracts of NT2 cells in vitro. As shown in
Figure 7C, treatment with increasing amounts of CASPASE-7 led
to a significant reduction of OCT4 signals, whereas similar
treatment with CASPASE-3 had no effect on OCT4 stability
Figure 4. Nucleoside drugs cause differential DNA methylation changes in NT2 cells. (A) COBRA analysis of four CpG islands in the HOXA
cluster in drug-treated and control NT2 cells, showing the demethylating activity of DAC and DZNep. ‘‘U’’ indicates unmethylated epialleles; ‘‘M’’
indicates methylated epialleles. (B) Genomic cytosine methylation levels decrease in DAC- and DZNep-treated NT2 cells. All measurements were
repeated at least three times, standard deviations are indicated by error bars. P-values (Student’s t-test) for the differences between control and
treated cells are shown on top. Only treatment with DZNep (DZN) and DAC (columns marked with an asterisk) lead to highly significant changes
(p#0.01). (C) DNMT1 trapping assay in NT2 cells showing depletion of DNMT1 only after DAC-treatment. DNMT1 in drug-treated and control cells was
detected by Western blot analysis of protein extracts from drug-treated cells. b-actin is shown as a loading control. (D) COBRA analysis of the same
CpG islands as in (A) in DZNep- and DAC-treated cells, control cells and cells depleted for SAHH and DNMT1, showing that depletion of SAHH also
leads to demethylation. ‘‘U’’ indicates unmethylated epialleles; ‘‘M’’ indicates methylated epialleles. Knockdown efficiencies for this experiment are
shown in Figure S3C.
doi:10.1371/journal.pone.0010726.g004
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conditions by both caspases, with CASPASE-3 showing a
significantly stronger effect (Figure 7C). These experiments
confirm that OCT4 and NANOG are direct substrates for
CASPASE-7 and support published data showing that NANOG is
targeted by CASPASE-3 [30].
Taken together, we identified CASPASE-7 and, to a lesser
extent, CASPASE-3 as important mediators of araC- and DAC-
Figure 5. Differentiation-inducing drugs cause DNA damage in NT2 cells and deplete NANOG and OCT4 by caspase-
dependent degradation. (A) Western blots showing the levels of cH2AX in untreated NT2 cells (cont.) and after 72h treatment with the
indicated drugs. Histone H3 was used as loading control. (B) Caspase-Glo-assay of NT2 cells treated for 48 hours with DZNep (DZN), araC,
DAC and RA. CASPASE-3/7-activity is shown as direct luminescence. Error bars represent standard deviations of at least 3 independent
experiments. P-values (Student’s t-test) for the differences between control and treated cells are shown on top. All observed changes are
significant (marked with an asterisk). (C) Western blots showing the levels of NANOG and OCT4 in untreated NT2 cells (cont.) and after 72h
treatment with the indicated drugs. b-actin was used as loading control. (D) Quantitative RT-PCR analysis of NANOG and OCT4 after 24, 48 and
72 hours of treatment with DZNep, araC, DAC and RA. Diagrams show fold differences compared to the untreated control. All qRT-PCR
measurements were repeated at least three times and internally normalised to the corresponding lamin-b and b-actin expression levels. P-
values for the expression differences between control and treated cells for highly significant cases (p#0.01) are shown. Asterisks indicate
expression values that are significantly different from controls. (E) Microscopic images (106 magnification) of NT2 cells expressing EGFP
under the control of the OCT4-promoter (first row) and the same cell line cells treated with RA (second row) and araC (third row) for 3 days.
The first column shows the light microscopic images (phase contrast), the second row EGFP fluorescence, the third column an overlay. EGFP-
signals persist in araC-treated cells.
doi:10.1371/journal.pone.0010726.g005
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differentiation.
Discussion
Differentiation-inducing compounds represent important tools
for molecular biology and promising drugs for cancer therapy
[4,19,38]. In this study, we compared the differentiation-inducing
mechanism of three compounds - DZNep, cytarabine and
decitabine - in a cancer stem cell model and identified a novel
pathway for drug-induced differentiation. Importantly, our results
show that drug-induced differentiation is not a consequence of
pharmacologic inhibition of DNA methylation and/or histone
methylation, but is triggered directly by the CASPASE-3/7-
dependent degradation of stem cell specific proteins. In particular,
we identified CASPASE-7 as a central enzyme specifically
inducing OCT4 depletion. Cytarabine and decitabine have
previously been reported to induce DNA damage and to trigger
caspase- and JNK-dependent apoptotic pathways [25,39–42].
Consistent with this notion, we can reverse the differentiation-
associated effects caused by araC and DAC by using inhibitors of
these pathways or by reducing levels of CASPASE-3 and
CASPASE-7 by dsRNA interference.
The potential of cytarabine to induce differentiation has been
known for a long time. The most prominent example is the use of
the drug for the differentiation of bone marrow progenitor cells in
leukaemias [4,43]. Decitabine has first been described to induce
differentiation more than 25 years ago in a landmark study linking
DNA demethylation to cellular differentiation [13]. Both cytara-
bine and decitabine are incorporated into DNA and lead to double
strand breaks (as monitored by the increase of hyperphosphory-
lated H2AX). Double strand breaks lead to the release of
mitochondrial cytochrome c into the cytosol, which triggers
apoptosome formation and mediates the activation of caspases-9, -
3 and -7 [34,35]. A recent publication describes that araC-induced
differentiation of acute myeloid leukaemia cells positive for
oncogenic RAS depends on p53 [44]. NT2 cells express p53
[45] and, even if we observed no effect of araC- or DAC-treatment
on p53 expression, we can not rule out a role for p53 in drug-
induced differentiation of NT2 cells. p53 is generally thought to
Figure 6. Expression analysis of key regulatory factors of proteolytic pathways. The graphs show a qRT-PCR expression analysis of p53,
CASPASE-3, CASPASE-7, JNKI, JNKII, EZH2 and the neuronal differentiation marker SNAP25 in drug-treated NT2 cells. Expression values after 3, 6, 12, 24,
48 and 72 hours of treatment are shown as fold increase compared to untreated cells. All qRT-PCR measurements were repeated at least three times
and internally normalised to the corresponding lamin-b and b-actin expression levels. P-values (Student’s t-test) for the expression differences
between control and treated cells for highly significant cases (p#0.01) are shown. Asterisks indicate expression values that are significantly different
from controls.
doi:10.1371/journal.pone.0010726.g006
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10726Figure 7. The effect of differentiation-inducing drugs in NT2 cells can be rescued by caspase and JNK inhibitors. OCT4 is a substrate of
CASPASE-7. (A) Quantitative RT-PCR expression analysis of the differentiation markers SNAP25, HOXA1 and of CASPASE-7 after 3 days of treatment
with araC, DAC or RA alone or in combination with caspase Inhibitors I and II (Casp-I, Casp-II), JNK inhibitor 1 (JNK), a combination of both caspase
inhibitors (Casp-I/II) and a mixture of all three inhibitors (all). Diagrams show fold differences compared to araC-, DAC- and RA-treatment alone. Co-
treatment with caspase inhibitors leads to reduced gene expression after araC and DAC treatment. All qRT-PCR measurements were repeated at least
three times and internally normalised to the corresponding lamin-b and b-actin expression levels. P-values (Student’s t-test) for the expression
differences between only drug-treated (2) and co-treated cells for highly significant cases (p#0.01) are shown. Asterisks indicate expression values
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[34]. Nevertheless, p53 function can differ from cell type to cell
type and accumulation of p53 can also activate pro-apoptotic
genes, which finally leads to caspase activation [34].
We had initially speculated that the drug-induced degradation
of EZH2 alone could lead to derepression of differentiation-
specific genes in embryonic cancer stem cells. However, DZNep
efficiently degraded EZH2 (without causing DNA damage in NT2
cells) and did not induce robust differentiation in our assays. The
exact mechanism of DZNep-dependent degradation of EZH2
remains to be elucidated. It was assumed that DZNep-mediated
inhibition of S-adenosylhomocysteine hydrolase (SAHH) leads to
the proteasomal degradation of EZH2 [14]. However, we found
that efficient knockdown of SAHH had no effect on EZH2 stability
or H3K27 trimethylation. This indicates that the pharmacologic
activity of DZNep is not limited to the inhibition of SAHH and
that the molecular mechanisms triggering DZNep-induced EZH2
degradation remain to be established. Also, direct reduction of
EZH2 by RNA interference did not trigger differentiation,
induced only very weak HOXA expression in NT2 cells and also
did not enhance the effects of OCT4 and NANOG depletion
(Figure S5). It is possible that repressive PRC1 complexes remain
attached to their target regions even in the absence of EZH2.
Alternatively, reduced EZH2-repression could be compensated by
its functionally redundant homologue EZH1 [46,47]. Of note, our
experiments confirm and extend earlier observations for a DNA
demethylating activity of DZNep [14]. This activity could indeed
be related to the DZNep-mediated inhibition of SAHH [18], as
suggested by our finding that depletion of SAHH by RNA
interference led to significant demethylation of HOXA-CpG-
islands.
Degradation of OCT4 and NANOG (detectable already after
24 hours) clearly preceded EZH2 degradation, HOXA activation
and upregulation of differentiation markers. Thus, degradation of
PRC2 components is most likely a consequence of the depletion of
stem cell markers, but nevertheless necessary for the subsequent
differentiation-specific epigenetic changes and the progression of
differentiation. As we show for retinoic acid, natural differentiation
is slow, even if OCT4 and NANOG are rapidly downregulated. This
downregulation, however, appeared mainly to be caused by
transcriptional repression. EGFP expression under the control of
the OCT4 regulatory region became clearly reduced after the
addition of RA, whereas expression persisted in araC-treated cells,
where transcriptional repression of the OCT4 gene is much slower
than proteolytic degradation of the gene product. In addition, RA-
induced OCT4 downregulation could not be rescued by caspase
inhibitors. In line with these findings, OCT4-degradation was also
not observed in RA-treated mouse embryonic stem cells [33]. We
found that RA-induced CASPASE-7-expression was not paralleled
by a similar increase in enzymatic activity, indicating that the
enzyme remained mostly inactive, which is also consistent with the
absence of EZH2 degradation in RA-treated cells at this time
point. Significantly reduced EZH2-levels could only be observed
after 2 weeks of RA-treatment (Figure S3D). Thus, PcG-
dependent repression is only slowly removed in naturally
differentiating NT2 cells, leading to a slow activation of neuronal
markers like NEFL and SNAP25. In summary, it appears plausible
that efficient and rapid differentiation, as induced by araC and
DAC, requires the concomitant proteolytic degradation of stem
cell factors and PcG proteins. Notably, the NANOG gene is
activated by OCT4 [5] and reduced OCT4 will therefore also lead
to reduced NANOG levels, as observed in our experiments.
In contrast to NANOG, OCT4 has so far not been described as
a caspase substrate and is not cleaved by CASPASE-3 in vitro [33].
Our results indicate that CASPASE-7, but not CASPASE-3, can
degrade OCT4 in vitro. This is in line with accumulating recent
evidence showing that these two enzymes are functionally distinct
[35,48]. The CASVM web server for support-vector-machines-
based prediction of caspase cleavage sites [49] predicts 5 cleavage
sites in OCT4 (Figure S8). When overexposing the blots shown in
Figure 7C, we observed a band of about 30 kD, which showed
increased intensity in the lanes with the CASPASE-7-treated
extracts (Figure S8C). As we observed this band only with an
OCT4-antibody directed against an N-terminal peptide of the
protein, but not with a C-terminal antibody (data not shown), it
most likely represents a caspase-dependent N-terminal degrada-
tion product of OCT4. A proteolytic cut at the predicted P1-site
272 within the homeodomain of OCT4 would result in a N-
terminal fragment of 30 kD (Figure S8B). This potential
CASPASE-7 cleavage site needs to be confirmed in future
experiments using recombinant OCT4 proteins bearing specific
point mutations at this recognition sequence.
Stem cell characteristics are increasingly recognised as an
important feature of human cancer cells and it is now widely
assumed that a stem cell population plays a major role in the
therapy resistance of tumours [50–52]. Strategies that target the
stem cell properties of cancer cells will thus be critically important
for translating this concept into therapeutical applications [3]. Our
results uncover a novel pathway that triggers differentiation of
embryonic cancer stem cells by the established anticancer drugs
cytarabine and decitabine. These findings not only shed light on
the mechanistic background of the biological effects caused by
these drugs, but also show that cytarabine and decitabine might be
useful in directly targeting the stem cell fraction of human
tumours.
Materials and Methods
Cell culture and drug treatment
The human cell lines NT2 D1, MCF7, HeLa and A549 were
maintained in Dulbecco’s Modified Eagle Medium (D-MEM, with
l-glutamine, 4500 mg/l d-glucose, without sodium pyruvat; Gibco)
supplemented with 10% fetal bovine serum and 200 U/ml
penicillin and 200 mg/ml streptomycin (all from Gibco) in a
humidified atmosphere of 5% CO2 in air. Lymphoblast cell lines
HL60 and HEL were kept in RPMI 1640 (Gibco), supplemented
with 10% fetal bovine serum, 2mM l-glutamine and 200 U/ml
penicillin and 200 mg/ml streptomycin (all from Gibco). NT2 cells
were induced to differentiate with 10 mM all-trans retinoic acid
(Sigma). Treatment of NT2 cells with araC, DAC, deoxycytidine
(all Sigma) and DZNep (National Cancer Institute, NSC 617989)
for 24, 48 or 72 hours was done under equitoxic conditions, i.e.
that are significantly different from controls. (B) Microscopic images (106magnification) of NT2 control cells (cont.) and NT2 cells treated for 72 h
with 1, 3 and 10 mM araC (upper panels) and NT2 cells co-treated for 72 h with a mixture of all three inhibitors (lower panels) are shown. The araC-
induced neuron-like morphology can be reverted to some degree by co-treatment with caspase and JNK inhibitors. (C) Western blots showing the
levels of OCT4 and NANOG in nuclear extracts from NT2 cells without treatment (cont.), in nuclear extracts incubated at 37uC alone in the presence of
1( +)o r2( ++) units of active recombinant human CASPASE-7 or CASPASE-3. b-actin was used as loading control. Antibodies specific for N-terminal
peptides of OCT4 and NANOG were employed. OCT4 signals are efficiently reduced only by CASPASE-7, whereas NANOG is degraded by both
caspases.
doi:10.1371/journal.pone.0010726.g007
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otherwise indicated). Substances, from aqueous stock solutions (5
or 50 mM), were added once to freshly seeded cells (2610
5 in a 6-
well culture plate in 2 ml of medium). Treatment with JNK
Inhibitor 1 (Alexis Biochemicals, 1 mM stock solution in water) at
1 mM, caspase Inhibitor I and II (Calbiochem, 5mM stock solution
in DMSO) at 5 mM and with the proteasome inhibitor Lactacystin
(Sigma L6785, 5 mg/ml stock solution in water) at 2 mM was done
2 hours before araC, DAC and RA were added. Inhibitors were
then added every day. Cells were harvested by trypsin treatment
and stored at 280uC.
Viability assay
Cell viability was assayed using the CellTiter-Blue Cell Viability
Assay (Promega). NT2, MCF7, HeLa or A549 cells were seeded
into 96-well assay plates at a density of 1000 cells per well in 100 ml
of medium. Test compounds araC, DAC, DZNep and dC were
added in increasing concentrations from 40 nM up to 100 mM
and cells were grown for 72 hours. Assays were performed in 6
biological replicates. After 3 days 20 ml of CellTiter-Blue reagent
was added to each well, mixed and incubated for 1–4 hours.
Absorbance at 570 and 600 nm was measured for each well and
resazurin reduction was calculated according to the instructions of
the kit. Viability was plotted as percentage compared to the
untreated cells.
RT PCR and real time analysis
Total RNA from drug-treated and untreated NT2 tissue culture
cells was prepared using the Trizol-reagent (Invitrogen) according
the manufacturer’s specifications. Real-time RT-PCR was per-
formed using the QuantiTect Reverse Transcription Kit (Qiagen).
One mg of total RNA was processed in 20 ml reactions according
to the manufacturer’s specifications. One ml of the cDNA was used
for a 10 ml PCR reaction using the Absolute QPCR SYBR Green
Mix (Thermo Scientific) and a Roche LightCycler 480. PCR
conditions: 1 cycle: 95uC615 minutes; 42 cycles: 95uC615 se-
conds, 60uC640 seconds, read; melting curve 65uC–95uC, read
every 1uC. Cycle threshold numbers for each amplification were
measured with LightCycler 480 software and relative quantifica-
tions of expression status of the genes under observation
comparing treated to non-treated cells were calculated and
normalised using lamin-b and b-actin as internal standards. qRT-
PCR measurements were repeated at least three times on
biological replicates. P-values were calculated using Student’s t-
test. For primer sequences see Table S1.
COBRA assay
For methylation analysis of CpG-rich regions in the HOXA
cluster genomic DNA was treated with sodium bisulfite and
analysed by COBRA [53]. PCR cycling conditions were 95uC for
30 seconds, 55–60uC for 30 seconds, and 72uC for 40 seconds for
35 cycles. The PCR products were gel purified and digested with
BstUI or TaqIa (New England Biolabs, Beverly, MA). Digested
PCR products were separated on 3% agarose gels. For primer
sequences see Table S2.
Capillary electrophoresis
Genomic DNA was prepared from cells using the DNeasy Kit
(Qiagen). Global methylation levels were determined by capillary
electrophoresis, as described previously [54]. Briefly, genomic
DNA was enzymatically hydrolysed to single nucleotides and the
nucleotides were derivatised with the fluorescent marker BODIPY
(Molecular Probes). Derivatised nucleotides were separated by
capillary electrophoresis and analysed in a Beckman PACE MDQ
Molecular Characterization System. P-values were calculated
using Student’s t-test.
DNMT1 trapping assay
NT2 D1 cells were grown and treated with the indicated
concentrations of DZNep, araC and DAC as described above.
After 3 days of treatment, cells were harvested, washed with PBS
and lysed for 30 minutes on ice in trapping buffer (PBS pH 7.4,
0,1% SDS, 0,5% NP40, 0,5% Sodiumdeoxycholate, 1 mM DTT
and Roche complete protease inhibitor cocktail). Insoluble debris
was pelleted and supernatants were separated by 8% SDS-PAGE
and transferred to polyvinylidene difluoride membranes (Milli-
pore). DNMT1 was detected using an antibody from Santa Cruz
Biotechnologies (C-17, sc-10222).
Protein depletion via siRNAs
For depletion of SAHH, DNMT1, EZH2, NANOG and OCT4
ON-TARGETplus SMARTpool siRNAs (Dharmacon) were used.
NT2 cells were seeded into 6-well plates at a density of 2610
5 in
2 ml of medium. siRNAs were transfected with the Dharma-
FECT1 transfection reagent (Dharmacon) according to the
manufacturer’s instructions. The final siRNA concentration was
50 nM. For combined knock downs the reactions were scaled up
accordingly. After 48 h or 72 hours cells were retransfected (48 h),
analysed by microscopy or harvested by trypsin treatment. Cell
pellets were then analysed by Western blot and RT-PCR.
Scrambled siRNAs for negative control experiments were also
obtained from Dharmacon. For depletion of araC-induced
CASPASE-3 and/or CASPASE-7 cells were treated for 6 hours
with 10 mM araC and were then transfected with scrambled
siRNAs, CASPASE-3 specific siRNAs, CASPASE-7 specific
siRNAs and a mix of both as described above. After transfection
the cells were grown for further 48 hours (without changing the
medium), analysed by microscopy, then harvested by trypsin
treatment and analysed by Western blot and RT-PCR.
Western blotting and antibodies
Pellets of cultured cells were lysed in SDS-PAGE-buffer, shock
frozen in liquid nitrogen and heated for 5 minutes at 95uC.
Samples were separated on 8–10% SDS-PAGE and transferred to
nitrocellulose (Whatman) or polyvinylidene difluoride (Millipore)
membranes. Proteins were immunodetected using specific anti-
bodies against EZH2 (Cell Signalling AC22), NANOG (abcam
ab21624), OCT4 (abcam ab18976), b-actin (abcam ab8226) and
SAHH (obtained from Michael Hershfield, Durham). Histones
were separated using 15% SDS-PAGE gels and transferred to
nitrocellulose (Whatman) membranes and immunodetected using
specific antibodies against H3 (Cell Signaling 9715), H3K27me3
(Upstate/Millipore 07-449) and cH2AX (Milipore, clone
JBW301). In some cases (Figures 2A and S2A) intensities of
protein bands were background corrected and quantified using
imageJ software (available at: http://rsb.info.nih.gov/ij/), nor-
malised against the actin loading control and calculated as
percentage of the signal for the untreated control.
ChIP assay
Crosslinked chromatin was prepared and immunoprecipitated
as described previously [9]. ChIP-grade antibodies specific for
H3K27me3 (07-449) and H3K4me3 (07-473) were purchased
from Upstate. Immunoprecipitates were finally dissolved in 30 ml
of TE buffer (10 mM Tris-HCL pH 8, 1 mM EDTA). One ml was
analysed by real time PCR using a primer pair specific for the
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TGTAATCCTATG; IPHOXA1prom_lo AGAAAGTTGGCA-
CAGTCACG) in 10 ml PCR reactions, using the Absolute QPCR
SYBR Green Mix (Themo Scientific) and a Roche LightCycler
480. PCR conditions: 1 cycle: 95uC615 minutes; 42 cycles:
95uC615 seconds/60uC640 seconds, read; melting curve 65uC–
95uC, read every 1uC. Cycle threshold numbers for each
amplification were measured with LightCycler 480 software and
enrichments were calculated as percentage of the input.
Caspase assay
Activity of CASPASE-3 and -7 in DZNep-, araC-, DAC- and
RA-treated NT2 cells was assayed with the Caspase-Glo 3/7 Assay
System (Promega) according to the instructions of the manufac-
turer. P-values were calculated using Student’s t-test.
Preparation of nuclear extracts and caspase treatment
Nuclei from NT2 cells were prepared according to Wu [55]. The
nuclear pellet was resuspended in lysis buffer (15 mM Tris-HCl
pH 7.4, 150 mM KCl, 15 mM NaCl, 5 mM MgCl2,0 . 1 m M
EGTA, 1 mM DTT and Roche complete protease inhibitor
cocktail; 1 ml per 10
6 starting cells) and lysed by adding ammonium
sulfate from a 4 M stock (pH 7,6) to a final concentration of 0.4 M
for 15 minutes on ice. The lysate was centrifuged 30 minutes at 4uC
and max. speed in a tabletop centrifuge and the supernatant was
precipitated with solid ammonium sulfate (0.3 g per ml of
supernatant). Proteins were pelleted at 4uC and max. speed in a
tabletop centrifuge for 15 minutes. The protein pellet was dissolved
in caspase buffer (50 mM Hepes pH 7,2, 50 mM NaCl, 0,1%
CHAPS, 10 mM EDTA, 5% glycerol and 10 mM DTT), 10 mlp e r
10
6 starting cells. Aliquots were stored at 280 uCo rd i r e c t l yu s e df o r
caspase digestion.
Aliquots corresponding to roughly 15 mg of total protein were
treated for 20 minutes with 1 or 2 units of active recombinant
human CASPASE-7 or CASPASE-3 (BioVision Research Prod-
ucts) in a total volume of 20 mla t3 7 uC. SDS-PAGE loading buffer
(86) was then added and the samples were separated on a 12%
SDS-PAGE gel and transferred to nitrocellulose. Proteins were
immunodetected using specific antibodies against NANOG
(abcam ab21624), OCT4 (abcam ab18976, N-terminal peptide),
OCT4 (abcam ab19857, C-terminal peptide) and b-actin (abcam
ab8226).
Histone preparation
Pellets of NT2-cells were washed once with cold PBS and then
lysed on ice in cold lysis buffer (10 mM Tris pH 6.5, 5.2 g/l
sodium bisulfite, 1% Triton-X100, 10 mM MgCl2, 486 g/l
sucrose, 1,2 g/l sodium butyrate). Lysates were centrifuged for
5 minutes at 4uC, max. speed in a tabletop centrifuge. Pellets were
washed 36 with cold lysis buffer and once with wash buffer
(10 mM Tris-HCL pH 7.4, 13 mM EDTA). Final pellets were
resuspended in 100 ml water, 1 mlH 2SO4 was added and the
samples were incubate on ice for 1 hour. Then, precipitates were
pelleted and the supernatants were transferred to new tubes.
Isolated histones were precipitated by adding 10 volumes of
acetone at 220uC over night. Precipitates were collected and
pellets were dissolved in water. After Bradford assay the histone
solution was set to 1 mg/ml, stabilised by adding PAGE loading
buffer to 16and stored at 220uC.
Generation of cell lines expressing OCT4-specific EGFP
Roughly 1610
6 NT2 cells were transfected with the plasmid
phOCT4-EGFP, containing a 4 kb fragment of the human OCT4
regulative region (23917 to +55) upstream of EGFP [35], using
the Effectene Transfection Kit (Qiagen) according to the
manufacturer’s instructions. Cells were plated into 10 cm culture
dishes and G148 (Sigma) selection was applied 24 hours after
transfection at 350 mg/ml. After 2 weeks of selection surviving
colonies were picked and expanded. One clone, showing
approximately 90% of EGFP positive cells, was chosen for
treatment with araC and RA.
Supporting Information
Figure S1 Nucleoside drugs affect the viability of MCF7, NT2,
HeLa and A549 cells in a similar manner. Cells were treated with
increasing concentrations of DZNep, araC, DAC (40 nM up to
100 mM) and viability was analysed via resazurin reduction after 3
days. Error bars represent standard deviations; deoxycytidine (dC)
was included as a mock treatment control.
Found at: doi:10.1371/journal.pone.0010726.s001 (5.78 MB TIF)
Figure S2 Effects of drug-treatment on EZH2-stability. DZNep-
mediated EZH2 depletion is not caused by SAHH inhibition. (A)
Western blots showing drug-induced degradation of EZH2 in the
cancer cell lines MCF7, A549, HeLa, HEL and HL60. Total
extracts from cells treated with DZNep, araC and DAC for three
days were analysed. b-actin was used as loading control. Below the
blots intesities of the EZH2-bands, normalised to the correspond-
ing b-actin bands, are indicated as percentage of the control
(cont.). (B) Western blot showing the effect of SAHH depletion (kd
SAHH) on EZH2 and H3K27me3 levels in MCF7 cells. Cells
were treated for 72 hours or 2 times 48 hours with siRNAs. Knock
down of EZH2 (kd EZH2) was used as positive control; b-actin
was used as a loading control. A scrambled siRNA was used as
negative control (kd cont.). Reduction of SAHH-levels has no
effect on EZH2 stability or H3K27me3 methylation.
Found at: doi:10.1371/journal.pone.0010726.s002 (5.42 MB TIF)
Figure S3 Effects of drug-treatment on HOX expression in NT2
cells. Efficiency of RNAi. Effect of RA-treatment on EZH2-
stability. (A) qRT-PCR expression analysis of HOXA1, HOXA2
and HOXA3 in NT2 cells after 3 days of drug incubation. Drug-
treatment at increasing concentrations (40 nM up to 20 mM) was
done for 3 days and corresponding total RNA was reverse
transcribed and analysed. Expression of all three HOX genes
increases with drug concentration. Y-axis values indicate fold
induction compared to the non-treated control. Deoxycytidine
(dC) was included as a mock treatment control. All qRT-PCR
measurements were repeated at least three times and internally
normalized to the corresponding lamin-b and b-actin expression
levels. Error bars represent standard deviations. (B) EZH2
transcription is efficiently reduced after siRNA mediated knock
down in NT2 cells. EZH2 expression was quantified by qRT-PCR
analysis in three independent knockdown experiments. Y-axis
values indicate fold reduction compared to the scrambled control
(kd cont.). (C) SAHH and DNMT1 transcription is efficiently
reduced after siRNA mediated knock down in NT2 cells.
Expression was quantified by qRT-PCR analysis in the knock-
down experiment used for the COBRA analysis shown in
figure 4D. Y-axis values indicate fold reduction compared to the
scrambled control (kd cont.). (D) Western blot showing the effect of
RA-treatment on the stability of EZH2 in NT2 cells during one
month of treatment. Reduced protein levels could be observed
after 3 weeks. b-actin was used as loading control.
Found at: doi:10.1371/journal.pone.0010726.s003 (5.08 MB TIF)
Figure S4 Differentiation-inducing drugs deplete NANOG and
OCT4 by caspase-dependent degradation in NT2 cells. (A)
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in cells treated for 6, 12, 24 and 48 hours with araC, DAC and
RA. b-actin was used as a loading control. The blot showing
retinoic acid induced changes (on the right) was reprobed after
NANOG-staining with OCT4 antibodies. Thus the b-actin
control is the same for this experiment. DAC- and araC-treated
OCT4 and NANOG blots are from two different experiments.
(B) Western blots showing that drug-induced degradation of
OCT4 and EZH2 in NT2 cells after 36 hours (OCT4) and
72 hours (EZH2) of treatment with araC is reduced (the signal is
restored) by caspase or JNK inhibitors. b-actin served as loading
control. (C) Western blots showing that RA-induced reduction of
OCT4 48 hours of treatment with retinoic acid is not significantly
reduced by caspase inhibitors I and II (Casp-I, Casp-II), JNK
inhibitor 1 (JNK), a combination of both Caspase inhibitors
(Casp-I/II) and a mixture of all three inhibitors (all). b-actin was
used as loading control.
Found at: doi:10.1371/journal.pone.0010726.s004 (5.11 MB TIF)
Figure S5 Depletion of stem cell factors induces differentiation
of NT2 cells. (A) Microscopic images (106magnification) of NT2
control cells (cont.) and NT2 transfected with a mix of scrambled
siRNAs (kd cont.), and siRNAS specific for DNMT1 (D), SAHH
(S), EZH2 (E), NANOG (N), OCT4 (O) and various combinations
of these. After transfection the cells were grown for 72 hours.
Knock down of OCT4 clearly induces neuronal phenotypes in
NT2 cells. (B) Quantitative RT-PCR expression analysis of the
differentiation marker SNAP25 and of DNMT1 (D), SAHH (S),
EZH2 (E), NANOG (N) and OCT4 (O) after the knock down
experiment described in (A). Diagrams show fold differences
compared to control cells (cont.). The transcription of DNMT1,
SAHH, EZH2, NANOG and OCT4 is efficiently reduced after
the respective siRNA mediated knock down. Expression of the
differentiation marker SNAP25 is weakly induced by NANOG
knock down, but significantly upregulated upon depletion of
OCT4, which is in line with the morphological observations. A
combined knock down of NANOG and OCT4, or NANOG,
OCT4 and EZH2 does not enhance the effect. qRT-PCR
measurements are from two independent experiments and were
internally normalised to the corresponding lamin-b and b-actin
expression levels. P-values (Student’s t-test) for the expression
differences between untreated cells (cont.) and transfected cells for
highly significant cases (p#0.01) are indicated. Asterisks indicate
expression values that are significantly different from controls.
Found at: doi:10.1371/journal.pone.0010726.s005 (5.49 MB TIF)
Figure S6 The effects of araC and DAC can not be rescued by
the proteasome inhibitor Lactacystin. (A) Quantitative RT-PCR
expression analysis of the differentiation markers SNAP25 and
HOXA1 in NT2 cells after 3 days of treatment with araC, DAC or
RA alone or in combination with the proteasome inhibitor
Lactacystin (LAC) or a combination of two caspase inhibitors
(Casp-I/II). Diagrams show fold differences compared to araC-,
DAC- and RA-treatment alone. Co-treatment with caspase
inhibitors leads to reduced gene expression after araC- and
DAC-treatment, whereas Lactacystin had no significant effect. All
qRT-PCR measurements were repeated at least three times and
internally normalised to the corresponding lamin-b and b-actin
expression levels. P-values (Student’s t-test) for the expression
differences between only drug-treated and co-treated cells for
highly significant cases (p#0.01) are indicated. Asterisks indicate
expression values that are significantly different from controls. (B)
Western blots showing that drug-induced degradation of OCT4 in
NT2 cells after 36 hours of treatment with araC is reduced (the
signal is restored) by the mix of caspase inhibitors (Casp), but not
by treatment with Lactacystin (LAC, middle). b-actin served as
loading control. (C) Western blots showing that drug-induced
degradation of EZH2 in NT2 cells after 72 hours of treatment
with araC is reduced (the signal is restored) by the mix of caspase
inhibitors (Casp), but not by treatment with Lactacystin (LAC,
middle). In contrast, DZNep-induced degradation of EZH2 is also
inhibited by Lactacystin (blot on the right). b-actin served as
loading control.
Found at: doi:10.1371/journal.pone.0010726.s006 (4.70 MB TIF)
Figure S7 The effect of differentiation-inducing drugs in NT2
cells can be rescued by depletion of CASPASE-3 and -7. (A)
Microscopic images (106 magnification) of NT2 control cells
(cont.) and NT2 cells treated for 54 h with 10 mM araC (araC).
The remaining images show cells that were treated for 6 hours
with 10 mM araC, then were transfected with a mix of scrambled
siRNAs (kd cont.), CASPASE-3 specific siRNAs (kd CASP-3),
CASPASE-7 specific siRNAs (kd CASP-7) and a mix of both (kd
CASP-3/7). After transfection the cells were grown for further
48 hours (with araC present). The araC-induced neuron-like
morphology can be reverted to some degree by the double knock
down. (B) Quantitative RT-PCR expression analysis of the
differentiation markers SNAP25, HOXA1 and of CASPASE-3
and CASPASE-7 after the treatment described in (A). Diagrams
show fold differences compared to araC-treatment alone.
CASPASE-3 and CASPASE-7 transcription is efficiently reduced
after the respective siRNA mediated knock down. Combined
knock down of both caspases leads to a significantly reduced araC-
induced expression of SNAP25, HOXA1. qRT-PCR measure-
ments are from two independent experiments and were internally
normalised to the corresponding lamin-b and b-actin expression
levels. P-values (Student’s t-test) for the expression differences
between only araC-treated (cont.) and transfected cells for highly
significant cases (p#0.01) are indicated. Asterisks indicate
expression values that are significantly different from controls.
(C) Western blots showing that araC-induced degradation of
OCT4 (under the conditions described in A) is reduced (the signal
is restored) by combined depletion of CASPASE-3 and CAS-
PASE-7. b-actin served as loading control.
Found at: doi:10.1371/journal.pone.0010726.s007 (4.08 MB TIF)
Figure S8 Potential caspase sites in the OCT4 protein. (A)
Predicted caspase substrate cleavage sites by the CASVM (server
for SVM Prediction of Caspase Substrates Cleavage Sites - http://
casbase.org/casvm/index.html) using the P4-P29and P14-P109-
trained classifiers are listed. The four amino acid core sequence
(P4-P1) and the position of the P1-site along the 360 amino acid
sequence of OCT4 are shown for each potential or predicted site.
(B) The positions of the 5 predicted cutting sites are indicated
below a sketch of the OCT4 protein. The POU-domain and the
homeodomain are highlighted. The calculated molecular weight in
kD for potentially originating N-terminal fragments after caspase
digest are indicated below the arrows. The potential site used by
CASPASE-7 is marked with an asterisk (C) Western blots showing
the levels of OCT4 in nuclear extract from NT2 cells without
treatment (cont.), in nuclear extract incubated at 37uC or treated
with 1 (+)o r2( ++) units of active recombinant human Caspase-7
at 37uC. An antibody specific for an N-terminal peptide of OCT4
was used. b-actin was used as loading control. The blot is identical
to the one shown in Fig. 7C but was exposed longer. A digestion
product of ca. 30 kD becomes visible, that is significantly increased
upon CASPASE-7 digestion (arrow with asterisk). This would
correlate with a cut at the predicted site within the homeodomain
of OCT4 (asterisk in B).
Found at: doi:10.1371/journal.pone.0010726.s008 (5.86 MB TIF)
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Found at: doi:10.1371/journal.pone.0010726.s009 (0.04 MB
DOC)
Table S2 COBRA primer pairs used in this study.
Found at: doi:10.1371/journal.pone.0010726.s010 (0.03 MB
DOC)
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